Cefazolin

Suppliers

Names

[ CAS No. ]:
25953-19-9

[ Name ]:
Cefazolin

[Synonym ]:
Cephazolin
7-(1-(1H)-Tetrazolylacetamido)-3-[2-(5-methyl-1,3,4-thiadiazolyl)thiomethyl]-D3-cephem-4-carboxylic Acid
Cephamezine
5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 3-[[(5-methyl-1,3,4-thiadiazol-2-yl)thio]methyl]-8-oxo-7-[[2-(1H-tetrazol-1-yl)acetyl]amino]-, (6R,7R)-
Cefazolinum
Cefazolina
Cephazoline
5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 3-[[(5-methyl-1,3,4-thiadiazol-2-yl)thio]methyl]-8-oxo-7-[(1H-tetrazol-1-ylacetyl)amino]-, (6R,7R)-
(6R,7R)-3-[(5-methyl-1,3,4-thiadiazol-2-yl)sulfanylmethyl]-8-oxo-7-[[2-(tetrazol-1-yl)acetyl]amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
Cefazoline
(6R,7R)-3-{[(5-Methyl-1,3,4-thiadiazol-2-yl)sulfanyl]methyl}-8-oxo-7-[(1H-tetrazol-1-ylacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
Cephazolidin
Ancef
MFCD00243010
EINECS 247-362-8
Cefazolin
(6R)-3-(5-methyl-[1,3,4]thiadiazol-2-ylsulfanylmethyl)-8-oxo-7t-(2-tetrazol-1-yl-acetylamino)-(6rH)-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid
(6R,7R)-3-{[(5-methyl-1,3,4-thiadiazol-2-yl)thio]methyl}-8-oxo-7-[(1H-tetrazol-1-ylacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
Cefamezin
Cefazolin Acid

Chemical & Physical Properties

[ Density]:
2.0±0.1 g/cm3

[ Melting Point ]:
198-200ºC

[ Molecular Formula ]:
C14H14N8O4S3

[ Molecular Weight ]:
454.507

[ Exact Mass ]:
454.029999

[ PSA ]:
234.93000

[ LogP ]:
1.13

[ Index of Refraction ]:
1.961

Toxicological Information

CHEMICAL IDENTIFICATION

RTECS NUMBER :
XI0389900
CHEMICAL NAME :
5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 3-(((5-methyl-1,3,4-thiadiazol-2-yl) thio)methyl)-8-oxo-7-(2-(1H-tetrazol-1-yl)acetamido)-
CAS REGISTRY NUMBER :
25953-19-9
LAST UPDATED :
199612
DATA ITEMS CITED :
7
MOLECULAR FORMULA :
C14-H14-N8-O4-S3
MOLECULAR WEIGHT :
454.54

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intravenous
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
3 gm/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
BYYADW Byoin Yakugaku. Hospital Pharmacology. (Yakuji Nippon Sha, 1-11 Izumi-cho, Kanda, Chiyoda-ku, Tokyo 101, Japan) V.1- 1975- Volume(issue)/page/year: 3,220,1978
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intramuscular
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
4 gm/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
BYYADW Byoin Yakugaku. Hospital Pharmacology. (Yakuji Nippon Sha, 1-11 Izumi-cho, Kanda, Chiyoda-ku, Tokyo 101, Japan) V.1- 1975- Volume(issue)/page/year: 3,220,1978 ** OTHER MULTIPLE DOSE TOXICITY DATA **
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intraperitoneal
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
164 gm/kg/26W-I
TOXIC EFFECTS :
Blood - normocytic anemia Blood - changes in serum composition (e.g. TP, bilirubin, cholesterol) Biochemical - Enzyme inhibition, induction, or change in blood or tissue levels - transaminases
REFERENCE :
NKRZAZ Chemotherapy (Tokyo). (Nippon Kagaku Ryoho Gakkai, 2-20-8 Kamiosaki, Shinagawa-Ku, Tokyo 141, Japan) V.1- 1953- Volume(issue)/page/year: 28(Suppl 7),1089,1980
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intravenous
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
44100 mg/kg/35D-I
TOXIC EFFECTS :
Blood - changes in serum composition (e.g. TP, bilirubin, cholesterol) Biochemical - Enzyme inhibition, induction, or change in blood or tissue levels - transaminases Related to Chronic Data - death
REFERENCE :
NKRZAZ Chemotherapy (Tokyo). (Nippon Kagaku Ryoho Gakkai, 2-20-8 Kamiosaki, Shinagawa-Ku, Tokyo 141, Japan) V.1- 1953- Volume(issue)/page/year: 28(Suppl 7),1007,1980
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intravenous
SPECIES OBSERVED :
Rodent - rabbit
DOSE/DURATION :
11200 mg/kg/28D-I
TOXIC EFFECTS :
Kidney, Ureter, Bladder - changes in tubules (including acute renal failure, acute tubular necrosis)
REFERENCE :
BYYADW Byoin Yakugaku. Hospital Pharmacology. (Yakuji Nippon Sha, 1-11 Izumi-cho, Kanda, Chiyoda-ku, Tokyo 101, Japan) V.1- 1975- Volume(issue)/page/year: 3,220,1978 *** NIOSH STANDARDS DEVELOPMENT AND SURVEILLANCE DATA *** NIOSH OCCUPATIONAL EXPOSURE SURVEY DATA : NOHS - National Occupational Hazard Survey (1974) NOHS Hazard Code - A1317 No. of Facilities: 33 (estimated) No. of Industries: 1 No. of Occupations: 1 No. of Employees: 528 (estimated) NOES - National Occupational Exposure Survey (1983) NOES Hazard Code - A1317 No. of Facilities: 318 (estimated) No. of Industries: 1 No. of Occupations: 5 No. of Employees: 16111 (estimated) No. of Female Employees: 13596 (estimated)

Safety Information

[ Hazard Codes ]:
Xn

[ Risk Phrases ]:
R20/21/22

[ Safety Phrases ]:
26-36

[ RIDADR ]:
NONH for all modes of transport

[ HS Code ]:
3004909090

Synthetic Route

Precursor & DownStream

Precursor

  • Cephazolin sodium
  • 2-(1H-tetrazol-1-yl)acetic pivalic anhydride
  • (6R-trans)-7-amino-3-[[(5-methyl-1,3,4-thiadiazol-2-yl)thio]methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid monohydrochloride
  • 2-Mercapto-5-methyl-1,3,4-thiadiazole
  • 7-TDA
  • Methyl Tetrazole-1-acetate
  • 7-Aminocephalosporanic acid
  • Cephalosporin C
  • cefazolin delta-2-methyl ester

DownStream

Customs

[ HS Code ]: 3004909090

Articles

Isolation of Escherichia coli strains with AcrAB-TolC efflux pump-associated intermediate interpretation or resistance to fluoroquinolone, chloramphenicol and aminopenicillin from dogs admitted to a university veterinary hospital.

J. Vet. Med. Sci. 76(7) , 937-45, (2014)

Understanding the prevalence of antimicrobial-resistance and the relationship between emergence of resistant bacteria and clinical treatment can facilitate design of effective treatment strategies. We...

Aspiration sclerotherapy combined with pasireotide to improve reduction of large symptomatic hepatic cysts (SCLEROCYST): study protocol for a randomized controlled trial.

Trials 16 , 82, (2015)

Aspiration sclerotherapy is an effective therapeutic option for large symptomatic hepatic cysts. However, incomplete cyst reduction following aspiration sclerotherapy is frequently reported. Strong po...

Skeletal muscle and plasma concentrations of cefazolin during cardiac surgery in infants.

J. Thorac. Cardiovasc. Surg. 148(6) , 2634-41, (2014)

To describe the pharmacokinetics and tissue disposition of prophylactic cefazolin into skeletal muscle in a pediatric population undergoing cardiac surgery.The subjects included 12 children, with a me...


More Articles


Related Compounds

  • Cefazolin
  • cefazolin sodium
  • Cefazolin-13C2,15N
  • Cefazolin Impurity 8
  • CEFAZOLIN IMPURITY D
  • Cefazolin Impurity 4
  • Methyl 3-azido-3-(4-phenylmethoxyphenyl)cyclobutane-1-carboxylate
  • (2R)-1-(3-Azidopropanoyl)pyrrolidine-2-carboxylic acid
  • tert-Butyl 3-(aminomethyl)-8-oxa-2-azaspiro[4.5]decane-2-carboxylate
  • 4-Bromo-1-benzothiophene-2-sulfonyl fluoride
  • [5-(5,6,7,8-Tetrahydronaphthalen-2-yl)thiophen-3-yl]methanamine
  • Methyl 8-formylimidazo[1,2-a]pyridine-3-carboxylate
  • Methyl 4-(fluorosulfonyl)pyrrolidine-2-carboxylate
  • Rel-(1R,3S)-3-(pyrimidin-2-ylcarbamoyl)cyclopentane-1-carboxylic acid
  • 3-Bromo-1-benzothiophene-2-sulfonyl fluoride
  • 4-Bromo-5-chloro-3-(chloromethyl)-1-methyl-1H-pyrazole
The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.